Scienture Holdings, Inc. engages in the provision of health services and pharmaceutical products. The company is headquartered in Commack, New York and currently employs 14 full-time employees. The company went IPO on 2020-02-18. Scienture, LLC is focused on developing and commercializing products for the treatment of central nervous system and cardiovascular diseases. Scienture LLC is developing a range of product candidates, including new potential treatments for hypertension, migraine, pain and thrombosis and other related disorders. The firm's product candidates include SCN- 102 (hypertension), SCN- 104 (CNS-Pain), SCN- 106 (Cardiovascular) and SCN- 107 (Pain). SCN-102 is an oral liquid formulation of losartan potassium in development for the treatment of hypertension. SCN-104 is a multi-dose pen-based delivery system for self-injection and increased patient convenience, which is in development for the acute treatment of migraine headaches.
Follow-Up Questions
Scienture Holdings Inc (SCNX)의 PER은 얼마입니까?
Scienture Holdings Inc의 PER은 2.0441입니다
Scienture Holdings Inc의 CEO는 누구입니까?
Mr. Surendra Ajjarapu은 2014부터 회사에 합류한 Scienture Holdings Inc의 Chairman of the Board입니다.
SCNX 주식의 가격 성능은 어떻습니까?
SCNX의 현재 가격은 $0.5667이며, 전 거래일에 increased 5.9% 하였습니다.
Scienture Holdings Inc의 주요 사업 주제나 업종은 무엇입니까?
Scienture Holdings Inc은 Health Care 업종에 속하며, 해당 부문은 Health Care입니다
